CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0268 (clinicaltrials.gov NCT No: NCT01149915)
Title:A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, in Patients with Advanced Leukemias
Principal Investigator:Marina Konopleva
Treatment Agent:Oral Hypoxyprobe-1; TH-302
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of TH-302 that can be given to patients with leukemia. The safety of this drug
will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloproliferative Diseases
Phase of Study:Phase I
Treatment Agents:Oral Hypoxyprobe-1
TH-302
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Threshold Pharmaceuticals, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
Dept:Leukemia
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults